(E)-3-(3-methoxy-4-{[3-(nitrooxy)propyl]oxy}phenyl)acrylic acid | 1374413-64-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(3-methoxy-4-{[3-(nitrooxy)propyl]oxy}phenyl)acrylic acid
• 英文别名: (E)-3-{3-methoxy-4-[3-(nitrooxy)propoxy]phenyl} acrylic acid；(E)-3-[3-methoxy-4-(3-nitrooxypropoxy)phenyl]prop-2-enoic acid
• CAS: 1374413-64-5
• 化学式: C₁₃H₁₅NO₇
• 分子量: 297.265
• InChiKey: WZAOGUQJVYJNJU-GQCTYLIASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (E)-3-(3-methoxy-4-{[3-(nitrooxy)propyl]oxy}phenyl)acrylic acid 在 sodium carbonate 、 sodium iodide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 生成 (E)-[5-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)benzyl)-2,4-dioxo-3-thiazolidinyl]methyl 3-[3-methoxy-4-(3-(nitrooxy)propoxy)phenyl]acrylate
  参考文献：
  名称：

  Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance

  摘要：

  Glucose intolerance is associated with metabolic syndrome and type 2 diabetes mellitus (T2DM) while some new therapeutic drugs, such as rosiglitazone (Rosi), for T2DM can cause severe cardiovascular side effects. Herein we report the synthesis of Rosi-ferulic acid (FA)-nitric oxide (NO) donor trihybrids to improve glucose tolerance and minimize the side effects. In comparison with Rosi, the most active compound 21 exhibited better effects on improving glucose tolerance, which was associated with its NO production, antioxidant and anti-inflammatory activities. Furthermore, 21 displayed relatively high stability in the simulated gastrointestinal environments and human liver microsomes, and released Rosi in plasma. More importantly, 21, unlike Rosi, had little stimulatory effect on the membrane translocation of aquaporin-2 (AQP2) in kidney collecting duct epithelial cells. These, together with a better safety profile, suggest that the trihybrids, like 21, may be promising candidates for intervention of glucose intolerance-related metabolic syndrome and T2DM. (C) 2018 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2018.10.006
• 作为产物：
  描述：

  methyl (E)-3-(4-(3-bromopropoxy)-3-methoxyphenyl)acrylate 在 silver nitrate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 乙腈 为溶剂， 生成 (E)-3-(3-methoxy-4-{[3-(nitrooxy)propyl]oxy}phenyl)acrylic acid
  参考文献：
  名称：

  Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance

  摘要：

  Glucose intolerance is associated with metabolic syndrome and type 2 diabetes mellitus (T2DM) while some new therapeutic drugs, such as rosiglitazone (Rosi), for T2DM can cause severe cardiovascular side effects. Herein we report the synthesis of Rosi-ferulic acid (FA)-nitric oxide (NO) donor trihybrids to improve glucose tolerance and minimize the side effects. In comparison with Rosi, the most active compound 21 exhibited better effects on improving glucose tolerance, which was associated with its NO production, antioxidant and anti-inflammatory activities. Furthermore, 21 displayed relatively high stability in the simulated gastrointestinal environments and human liver microsomes, and released Rosi in plasma. More importantly, 21, unlike Rosi, had little stimulatory effect on the membrane translocation of aquaporin-2 (AQP2) in kidney collecting duct epithelial cells. These, together with a better safety profile, suggest that the trihybrids, like 21, may be promising candidates for intervention of glucose intolerance-related metabolic syndrome and T2DM. (C) 2018 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2018.10.006

文献信息

• 一种法舒地尔衍生物及其制备方法和应用
  申请人：沈阳药科大学

  公开号：CN116375685A

  公开（公告）日：2023-07-04

  本发明提供了一种法舒地尔衍生物及其制备方法和应用，属于医药合成技术领域。本发明提供的法舒地尔衍生物，具有式I所示结构；法舒地尔是ROCK抑制剂，通过抑制ROCK起到强效扩张血管、保护神经元细胞、促进轴突再生、保护缺血脑组织的作用。本发明以法舒地尔作为母核结构，制得的法舒地尔衍生物自由基清除效率高，副作用小，抑制炎症因子效力强，抗氧化应激能力好，能够用于制备神经保护及治疗脑卒中疾病的药物。
• Tacrine–Ferulic Acid–Nitric Oxide (NO) Donor Trihybrids as Potent, Multifunctional Acetyl- and Butyrylcholinesterase Inhibitors
  作者：Yao Chen、Jianfei Sun、Lei Fang、Mei Liu、Sixun Peng、Hong Liao、Jochen Lehmann、Yihua Zhang

  DOI：10.1021/jm300106z

  日期：2012.5.10

  In search of multifunctional cholinesterase inhibitors as potential anti-Alzheimer drug candidates, tacrine-ferulic acid-NO donor trihybrids were synthesized and tested for their cholinesterase inhibitory activities, release of nitric oxide, vasodilator properties, cognition improving potency, and hepatotoxicity. All of the novel target compounds show higher in vitro cholinesterase inhibitory activity than tacrine. Three selected compounds (3a, 3f, and 3k) produce moderate vasorelaxation in vitro, which correlates with the release of nitric oxide. Compared to its non-nitrate dihybrid analogue (3u), the trihybrid 3f exhibits better performance in improving the scopolamine-induced cognition impairment (mice) and, furthermore, less hepatotoxicity than tacrine.